Chemotherapy for metastatic melanoma

Expert Review of Anticancer Therapy

Volumn 6, Issue 1, 2006, Pages 121-130

  Mandarà, Marta ^a   Nortilli, Rolando ^a   Sava, Teodoro ^a   Cetto, Gian Luigi ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

Chemotherapy; Metastatic melanoma

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BLEOMYCIN; CANCER VACCINE; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DENDRITIC CELL VACCINE; FOTEMUSTINE; HEAT SHOCK PROTEIN VACCINE; INTERFERON; INTERLEUKIN 2; LOMUSTINE; NITROSOUREA DERIVATIVE; OBLIMERSEN; PLATINUM DERIVATIVE; TAMOXIFEN; TAXANE DERIVATIVE; TEMOZOLOMIDE; THALIDOMIDE; TRIAZENE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; VINDESINE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; BIOLOGICAL RESPONSE MODIFIER;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BIOLOGICAL THERAPY; BLOOD TOXICITY; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG RESPONSE; HORMONE INHIBITION; HUMAN; MELANOMA; METASTASIS; MONOTHERAPY; REVIEW; UNSPECIFIED SIDE EFFECT; COMORBIDITY; CONTROLLED CLINICAL TRIAL; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; SKIN TUMOR; SURVIVAL;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL RESPONSE MODIFIERS; COMORBIDITY; HUMANS; MELANOMA; NEOPLASM METASTASIS; RANDOMIZED CONTROLLED TRIALS; SKIN NEOPLASMS; SURVIVAL; TAMOXIFEN;

EID: 85047691355     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.6.1.121     Document Type: Review

References (75)

1. Jemal A, Devesa SS, Hartge P et al. Recent trends in cutaneous melanoma incidence among whites in the United States. J. Natl Cancer Inst. 93, 678-683 (2001).
2. Florez A, Cruces M. Melanoma epidemic: true or false? Int. J. Dermatol. 43(6), 405-407 (2004).
3. Welch HG, Woloshin S, Schwartz LM. Skin biopsy rates and incidence of melanoma: population based ecological study. Br. Med. J. 331(7515), 481 (2005).
4. Jemal A, Clegg LX, Ward E et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 101(1), 3-27 (2004).
5. Buzaid AC, Anderson CM. The changing prognosis of melanoma. Curr. Oncol. Rep. 2(4), 322-328 (2000).
6. Anderson CM, Buzaid AC, Legha SS et al. Systemic treatments for advanced cutaneous melanoma. Oncology 9(11), 1149-1158 (1995).
7. Eggermont AM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur. J. Cancer 40(12), 1825-1836 (2004).
8. Bleehen NM, Newlands ES, Lee SM et al. Cancer Research Campaign Phase II trial of temozolomide in metastatic melanoma. J. Clin. Oncol. 13(4), 910-913 (1995).
9. Chang A, Hunt M, Parkinson DR et al. Phase II trial of carboplatin in patients with metastatic malignant melanoma. A report from the Eastern Co-operative Oncology Group. Am. J. Clin. Oncol. 16(2), 152-155 (1993).
10. Nelimark RA, Peterson BA, Vosika GJ et al. Vindesine for metastatic malignant melanoma. A Phase II trial. Am. J. Clin. Oncol. 6(5), 561-564 (1983).
11. Nathan FE, Mastrangelo MJ. Systemic therapy in melanoma. Semin. Surg. Oncol. 14(4), 319-327 (1998).
12. Falkson CI, Falkson G, Falkson HC. Phase II trial of fotemustine in patients with metastatic malignant melanoma. Invest. New Drugs 12(3), 251-254 (1994).
13. Legha SS, Ring S, Papadopoulos N et al. A Phase II trial of taxol in metastatic melanoma. Cancer 65(11), 2478-2481 (1990).
14. Bedikian AY, Weiss GR, Legha SS et al. Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy. J Clin. Oncol. 13(12), 2895-2899 (1995).
15. Avril MF, Aamdal S, Grob JJ et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a Phase III study. J. Clin. Oncol. 22(6), 1118-1125 (2004).
16. Middleton MR, Grob JJ, Aaronson N et al. Randomized Phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J. Clin. Oncol. 18(1), 158-166 (2000).
17. Luikart SD, Kennealey GT, Kirkwood JM. Randomized Phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma. J. Clin. Oncol. 2(3), 164-168 (1984).
18. Lopez M, Perno CF, Di Lauro L et al. Controlled study of DTIC versus DTIC plus epirubicin in metastatic malignant melanoma. Invest. New Drugs 2(3), 319-322 (1984).
19. Chapman PB, Einhorn LH, Meyers ML et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J. Clin. Oncol. 17(9), 2745-2751 (1999).
20. Hwu WJ, Krown SE, Menell JH et al. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J. Clin. Oncol. 21(17), 3351-3356 (2003).
21. Hwu WJ, Lis E, Menell JH et al. Temozolomide plus thalidomide in patients with brain metastases from melanoma: a Phase II study. Cancer 103(12), 2590-2597 (2005).
22. Bafaloukos D, Tsoutsos D, Kalofonos H et al. Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized Phase II study of the Hellenic Co-operative Oncology Group. Ann. Oncol. 6(6), 950-957 (2005).
23. Mornex F, Thomas L, Mohr P et al. A prospective randomized multicentre Phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melanoma Res. 13(1), 97-103 (2003).
24. Lotze MT, Dallal RM, Kirkwood JM et al. Cutaneous melanoma. In: Cancer: Principles & Practice of Oncology. 6th ed. Lippincott, Williams & Wilkins, PA, USA, 2012-2069 (2001).
25. Jungnelius U, Rinborg U, Aamdal S et al. Dacarbazine-vindesine versus dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A randomised Phase III trial. Eur. J. Cancer. 34(9), 1368-1374 (1998).
26. Jelic S, Babovic N, Kovcin V et al. Comparison of the efficacy of two different dosage dacarbazine-based regimens and two regimens without dacarbazine in metastatic melanoma: a single-centre randomized four-arm study. Melanoma Res. 12(1), 91-98 (2002).
27. Agarwala SS, Ferri W, Gooding W et al. A Phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma. Cancer 85(9), 1979-1984 (1999).
28. Wittes RE, Wittes JT, Golbey RB. Combination chemotherapy in metastatic malignant melanoma: a randomized study of three DTIC-containing combination. Cancer 41(2), 415-421 (1978).
29. McKelvey EM, Luce JK, Vaitkevicius VK et al. Bis chloroethyl nitrosourea, vincristine, dimethyl triazeno imidazole carboxamide and chlorpromazine combination chemotherapy in disseminated malignant melanoma. Cancer 39(1), 5-10 (1977).
30. Eigentler T, Caroli U, Radny P et al. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomized clinical trials. Lancet Oncol. 4(12), 748-59 (2003).
31. Del Prete SA, Maurer LH, O'Donnel J et al. Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat. Rep. 68(11), 1403-1405 (1984).
32. Legha SS, Ring S, Papadopoulos N et al. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer 64 (10), 2024-2029 (1989).
33. Chiarion-Sileni V, Nortilli R, Aversa SM et al. Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients. Melanoma Res. 11(2), 189-196 (2001).
34. Creagan ET, Suman VJ, Dalton RJ et al. Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma. J. Clin. Oncol. 17(6), 1884-1990 (1999).
35. Rusthoven JJ, Quirt IC, Iscoe NA et al. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 14(7), 2083-2090 (1996).
36. Johnston SR, Constenla DO, Moore J et al. Randomized Phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon α (IFN-α) and interleukin (IL-2) in patients with metastatic melanoma. Br. J. Cancer 77(8), 1280-1286 (1998).
37. Middleton MR, Lorigan P, Owen J et al. A randomized Phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. Br. J. Cancer 82 (6), 1158-1162 (2000).
38. Buzaid AC, Legha SS, Winn R et al. Cisplatin (C), vinblastine (V), dacarbazine (D) (CVD) versus dacarbazine alone in metastatic melanoma: preliminary results Phase III cancer community Oncology program (CCOP). Proceedings of the 29th American Society of Clinical Oncology. FL, USA, 1328 abstract (1993).
39. Eton O, Legha SS, Bedikian AY et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a Phase III randomized trial. J. Clin. Oncol. 20(8), 2045-2052 (2002).
40. Rumke P, Kleeberg UR, MacKie RM et al. Tamoxifen as a single agent for advanced melanoma in postmenopausal women. A Phase II study of the EORTC Malignant Melanoma Co-operative Group. Melanoma Res. 2(3), 153-156 (1992).
41. Cocconi G, Bella M, Calabresi F et al. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N. Engl. J. Med. 327(8), 516-523 (1992).
42. McClay EF, Jones JA, Winski PJ et al. Determinants of tamoxifen sensitivity control the nature of the synergistic interaction between tamoxifen and cisplatin. Cancer Res. 56(17), 3993-3997 (1996).
43. McClay EF, Mastrangelo MJ, Berd D et al. Effective combination chemo/hormonal therapy for malignant melanoma: experience with three consecutive trials. Int. J. Cancer. 50(4), 553-556 (1992).
44. Falkson CI, Ibrahim J, Kirkwood JM et al. Phase III trial of dacarbazine versus dacarbazine with interferon α-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon α-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Co-operative Oncology Group study. J. Clin. Oncol. 16(5), 1743-1751 (1998).
45. Lens MB, Remain T, Husain AF. Use of tamoxifen in the treatment of malignant melanoma. Cancer 98(7), 1355-1361 (2003).
46. Kirkwood JM, Strawderman MH, Ernstoff MS et al. Interferon α-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Co-operative Oncology Group Trial EST 1684. J. Clin. Oncol. 14(1), 7-17 (1996).
47. Bajetta E, Di Leo A, Zampino MG et al. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon α-2a in the treatment of advanced melanoma. J. Clin. Oncol. 12(4), 806-811 (1994).
48. Thomson DB, Adena M, McLeod GR et al. Interferon-α 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial. Melanoma Res. 3(2), 133-138 (1993).
49. Young AM, Marsden J, Goodman A et al. Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-α (IFN-α) in metastatic melanoma. Clin. Oncol. (R. Coll. Radiol.) 13(6), 458-465 (2001).
50. Huncharek M, Caubet JF, McGarry R. Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials. Melanoma Res. 11(1), 75-81 (2001).
51. Keilholz U, Stoter G, Punt J et al. Recombinant interleukin-2-based treatments for advanced melanoma: the experience of the European Organization for Research and Treatment of Cancer Melanoma Co-operative Group. Cancer J. Sci. Am. 3(S1), S22-S28 (1997).
52. Atkins MB, Lotze MT, Dutcher JP et al. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17(7), 2105-2116 (1999).
53. Rosenberg SA, Yang JC, Topalian SL et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA 271(12), 907-913 (1994).
54. Sparano JA, Fisher RI, Sunderland M et al. Randomized Phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon α-2a in patients with advanced melanoma. J. Clin. Oncol. 11(10), 1969-1977 (1993).
55. Keilholz U, Conradt C, Legha SS et al. Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J. Clin. Oncol. 16, 2921-2929 (1998).
56. Atkins MB, Lee S, Flaherty LE et al. A prospective randomized Phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD), IL-2 and interferon alpha-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): an ECOG-co-ordinated intergroup trial. Proceedings of the 39th American Society of Clinical Oncology. IL, USA, 2847 abstract (2003).
57. Keilholz U, Goey SH, Punt CJ et al. Interferon α-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Co-operative Group. J. Clin. Oncol. 15, 2579-2588 (1997).
58. Keilholz U, Punt CJ, Gore M et al. Dacarbazine, cisplatin and IFNa-2b with or without IL-2 in advanced melanoma: final analysis of EORTC randomized Phase III trial 18951. Proceeding of the 39th American Society of Clinical Oncology. IL, USA, 2848 abstract (2003).
59. Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon α-2b. J. Clin. Oncol. 17, 968-975 (1999).
60. Tsao H, Atkins MB and Sober AJ. Management of cutaneous melanoma. N. Engl. J. Med. 351(10), 998-1012 (2004).
61. Parmiani G, Castelli C, Dalerba P et al. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J. Natl. Cancer Inst. 94(11), 805-818 (2002).
62. Kao JY, Zhang M, Chen CM et al. Superior efficacy of dendritic cell-tumor fusion vaccine compared with tumor lysate-pulsed dendritic cell vaccine in colon cancer. Immunol. Lett. 101(2), 154-159 (2005).
63. Schadendorf D, Nestle FO, Broecker EB et al. Dacarbacine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) as first-line treatment of patients with metastatic melanoma: Results of a prospective-randomized Phase III study. Proceedings of the 40th American Society of Clinical Oncology. LA, USA, 7508 abstract (2004).
64. Millward MJ, Bedikian AY, Conry RM et al. Randomized multinational Phase III trial of dacarbazine with or without bcl-2 antisense (oblimersen sodium) in patients with advanced malignant melanoma: analysis of long-term survival. Proceedings of the 40th American Society of Clinical Oncology. LA, USA, 7505 abstract (2004).
65. Folkman J. Angiogenesis-dependent diseases. Semin. Oncol. 28, 536-542 (2001).
66. Pawlak WZ, Legha SS. Phase II study of thalidomide in patients with metastatic melanoma. Melanoma Res. 14(1), 57-62 (2004).
67. Danson Lorigan, Arance et al. Randomized Phase II study of temozolomide given every 8 h or daily with either interferon α-2b or thalidomide in metastatic malignant melanoma. J. Clin. Oncol. 21(13), 2551-2557 (2003).
68. Carson WE, Biber J, Shah N et al. A Phase II trial of a recombinant humanized monoclonal antivascular endothelial growth factor (VEGF) antibody in patients with malignant melanoma. Proceedings of the 39th American Society of Clinical Oncology. IL, USA, 2873 abstract (2003).
69. Gorden A, Osman I, Gai W et al. Analysis of BRAF and N-RAS mutations in metastatic -melanoma tissues. Cancer Res. 63, 3955-3957 (2003).
70. Ahmad T, Marais R, Pyle L et al. BAY 43-9006 in patients with advanced melanoma: the Royal Marsden experience. Proceedings of the 40th American Society of Clinical Oncology. LA, USA, 7506 abstract (2004).
71. Flaherty K, Brose MS, Schuchter L et al. Phase I/II trial of BAY 43-9006, carboplatin and paclitaxel demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma. Proceedings of the 40th American Society of Clinical Oncology. LA, USA, 7507 (2004).
72. Atzpodien J, Neuber K, Kamanabrou D et al. Combination chemotherapy with or without sc. IL-2 and IFN-α: results of a prospectively randomized trial of the Co-operative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM). Br. J. Cancer 86(2), 179-84, (2002).
73. Hauschild A, Garbe C, Stolz W et al. Dacarbazine and interferon a with or without interleukin-2 in metastatic melanoma: a randomized Phase III multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG). Br. J. Cancer 84(8), 1036-1042 (2001).
74. Ridolfi R, Chiaron-Sileni V, Guida M et al. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon α-2b in advanced melanoma out-patients: results from an Italian multicenter Phase III randomized clinical trial. J. Clin. Oncol. 20(6), 1600-1607 (2002).
75. Dorval T, Negrier S, Chevreasu C et al. Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-α-2a in patients with metastatic melanoma: a Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study. Cancer 85(5), 1060-1066 (1999).